Corneal Ulcer and Ulcerative Keratitis in Emergency Medicine

Back

Background

A corneal ulcer is a loss of corneal tissue, often associated with inflammation, and ulcerative keratitis is the general term for the group of disease processes leading to corneal ulceration, as well as the term for the inflammation that accompanies ulceration.

Most corneal ulcers are infectious, including bacterial and viral etiologies. Noninfectious ulcers may be due to chemical burns or autoimmune, toxic, neurotrophic, or other causes.

Because of its potential to permanently impair vision or progress to perforation and an open globe, a corneal ulcer is considered an ophthalmologic emergency.

Pathophysiology

Although corneal ulcers may occasionally be sterile, most are infectious in etiology.

Bacterial keratitis is the most important etiology to exclude in the emergency department (ED). Corneal infections and infectious keratitis are often presumed to be bacterial until proven otherwise.

Bacterial corneal ulcers may follow a break in the corneal epithelium, thereby providing an entry for bacteria. The traumatic episode may be minor, such as a minute abrasion from a small foreign body, or may result from such causes as tear insufficiency, malnutrition, or contact lens use. Increased use of soft contact lenses in recent years has led to a dramatic rise in the occurrence of corneal ulcers, particularly due to Pseudomonas aeruginosa.[1]

Common bacterial isolates cultured from patients with keratitis include P aeruginosa, coagulase-negative staphylococci, Staphylococcus aureus, Streptococcus pneumoniae, and Enterobacteriaceae (including Klebsiella, Enterobacter, Serratia, and Proteus). Klebsiella pneumoniae mucoid phenotype and its ability to form biofilm may be important in producing corneal ulceration. Agents such as N-acetylcysteine, may have a role in treatment because they inhibit biofilm formation.

Ulcers due to viral infection occur on a previously intact corneal epithelium.

Herpes simplex and varicella-zoster viruses can both cause a significant infectious keratitis.[2]

With the introduction of topical corticosteroid drugs in the treatment of eye disease, fungal corneal ulcers have become more common. Fungi (Fusarium and Candida species) and parasitic amoeba (Acanthamoeba) have been found in a small number of patients and frequently present with more severe symptoms.

Peripheral ulcerative keratitis (PUK) is a complication of rheumatoid arthritis (RA) that can lead to rapid corneal destruction (corneal melt) and perforation with loss of vision. An example is shown in the image below.



View Image

Peripheral ulcerative keratitis in the right eye of a patient with rheumatoid arthritis. Glue has been placed.

Mooren ulcer is an idiopathic ulceration of the peripheral cornea that may result from an autoimmune reaction or may be associated with hepatitis C virus. It is a rapidly progressive, painful, ulcerative keratitis, which initially affects the peripheral cornea and may spread circumferentially and then centrally. Mooren ulcer can only be diagnosed in the absence of an infectious or systemic cause.

Epidemiology

Incidence

United States

Approximately 25,000 Americans develop infectious keratitis annually. The annual incidence of microbial keratitis associated with contact lens use is approximately 2-4 infections per 10,000 users of soft contact lenses and 10-20 infections per 10,000 users of extended-wear contact lenses. Approximately 10% of these infections result in the loss of 2 or more lines of visual acuity.[3]

International

A study from the United Kingdom reported factors associated with an increased risk of a corneal invasive event in the population studied. The factors included use of extended-wear hydrogel lenses, male gender, smoking, and the late winter months.[4]

Morbidity

Corneal scarring and vision loss are possible consequences.

Sex

Studies from the United Kingdom suggest that males who wear extended-wear contact lenses are at increased risk of forming a corneal ulcer.

Other studies suggest that males are at increased risk due to the higher probability of sustaining ocular trauma.

Age

Corneal injury or infection can affect people of all ages. A bimodal distribution is observed. The age groups with a higher prevalence of disease are likely tied to risk factors, those in the first group (< 30 y) who are more likely to be contact lenses wearers and/or sustain ocular trauma, and those in the second group (>50 y) who are more likely to undergo eye surgery.

Contact lenses

Infectious keratitis is significantly more common in contact lens wearers.

Authors from the United Kingdom also report an 8 times higher incidence of corneal invasive event in contact lens wearers who sleep in contact lenses compared with wearers who use lenses only during the waking hours.[5]

Prognosis

Corneal ulcerations should improve daily and should heal with appropriate therapy. If healing does not occur or the ulcer extends, consider an alternate diagnosis and treatment.

Patient Education

For excellent patient education resources, visit eMedicineHealth's Eye and Vision Center. Also, see eMedicineHealth's patient education articles Anatomy of the Eye, Corneal Ulcer, and Iritis.

History

The history may suggest an etiology and may reveal clues concerning the likelihood of an infectious etiology.

Important questions include the following:

Symptoms

Symptoms may include any of the following:

Contact lens use

Contact lens use, including the following:[6]

Medication use

Current medications, including systemic and especially ocular medications, particularly steroids

Past medical history

See the list below:

Social history

Smoking is an important risk factor.

Physical

The physical examination findings may suggest an etiology, including the likelihood of an infectious etiology.

In addition, a careful physical examination is necessary to assess severity, ie, the risk of perforation and the risk of vision loss.

The physical examination should include measurement of visual acuity, external ex­amination, and slit-lamp examination.[8]

Visual acuity

Visual acuity should be tested at triage, and, if in doubt, the physician should repeat the measurement personally. Visual function is variably affected, depending on the location of the ulcer and whether associated corneal and uveal inflammation is present. Obtain visual acuities on all patients with ocular complaints.

Gross examination

Gross examination should include the eyelids, surface of the eye, pupils, extraocular muscles, and fundi. Examination of the lids and the conjunctiva may reveal associated inflammation in these locations. The eye is often erythematous, and ciliary injection is often present. Pupillary constriction may be present secondary to ciliary spasm and iritis. Purulent exudate may be seen in the conjunctival sac or on the surface of the ulcer, and infiltration of the stroma may result in a whitish opacity of the cornea.

Slit lamp examination

Slit lamp examination should follow gross examination in all suspected cases.

Clinical features suggestive of bacterial keratitis include suppurative stromal infiltrate (particularly >1 mm) with indistinct edges, edema, and white cell infiltration in surrounding stroma. An epithelial defect is typically present. An anterior chamber reaction is often seen.[8] The ulcer often is round or oval, and the border is generally demarcated sharply, with the base appearing ragged and gray. Slit lamp examination may reveal findings of iritis, and hypopyon may be present. Hypopyon is an accumulation of inflammatory cells in the anterior chamber that produces a layered meniscus in the inferior anterior chamber.

Slit-lamp examination should include assessment of the following:[8]

Fluorescein staining of the cornea

Fluorescein staining of the cornea is usually performed and may provide additional information about other factors, such as the presence of dendrites, pseudodendrites, loose or exposed sutures, foreign body, and any epithelial defect.[8] Fluorescein staining may reveal characteristic findings, such as the dendritic ulcer of herpes simplex virus infection.

Additional tips

Always examine the contralateral eye.

In a patient who cannot sit up in a slit lamp, and a portable slit lamp is not available, a Wood lamp may be the only available tool for fluorescein examination.

Causes

Although some corneal ulcers are sterile, most are infectious in etiology. Risk factors for corneal ulcer include contact lens use, HIV infection, trauma, ocular surface disease, and ocular surgery.[1] Overnight contact lens wear has been shown to be associated with an increased risk. Other identified risk factors include older age, male gender, smoking, low socioeconomic class, and inadequate contact lens hygiene.

Bacterial keratitis

Bacterial infection is the most important etiology to exclude in the ED. Corneal infections and infectious keratitis are often presumed to be bacterial until proven otherwise.

Bacterial corneal ulcer

Bacterial corneal ulcers may follow a break in the corneal epithelium, thereby providing an entry for bacteria. The traumatic episode may be minor, such as a minute abrasion from a small foreign body, or may result from such causes as tear insufficiency, malnutrition, or contact lens use. Increased use of soft contact lenses in recent years has led to a dramatic rise in the occurrence of corneal ulcers, particularly due to Pseudomonas aeruginosa.[1]

Bacteria that can penetrate through intact corneal epithelium include Corynebacterium diphtheriae, Haemophilus influenzae, Neisseria gonorrhoea, Neisseria meningitidis, and Listeria species.

Common bacterial isolates cultured from patients with keratitis include P aeruginosa, coagulase-negative staphylococci, S aureus, S pneumoniae, and Enterobacteriaceae (including Klebsiella, Enterobacter, Serratia, and Proteus). K pneumoniae mucoid phenotype and its ability to form biofilm may be important in producing a corneal ulceration. Agents such as N-acetylcysteine may have a role in treatment because they inhibit biofilm formation.

Viral corneal ulcer

Corneal ulcers due to viral infection often occur on a previously intact corneal epithelium.

Herpes simplex and varicella-zoster viruses can both cause significant infectious keratitis.[2]

Fungal and parasitic corneal ulcer

With the introduction of topical corticosteroid drugs in the treatment of eye disease, fungal corneal ulcers have become more common. Fungi (Fusarium and Candida species) and parasitic amoeba (Acanthamoeba) have been found in a small number of patients and frequently present with more severe symptoms.

Complications

The complications of corneal ulcer can be devastating. Corneal perforation, although rare, can occur. Corneal scarring may develop, resulting in partial or complete loss of vision. Anterior and posterior synechiae, glaucoma, and cataracts also can develop.

Laboratory Studies

Culture

Most community-acquired cases of bacterial keratitis resolve with empiric therapy and are managed without cultures. However, cultures are indicated in cases that involve a corneal infiltrate that is central and large and extends to the middle to deep stroma, cases that are unresponsive to antibiotic therapy, and cases that have atypical clinical features suggestive of fungal, amoebic, or mycobacterial keratitis.[8] Consult with an ophthalmologist.

Approach Considerations

Appropriate care of a corneal ulcer depends on an assessment of risk of visual loss and perforation.

Emergency Department Care

Consulting with an ophthalmologist from the ED is the best practice whenever a corneal ulcer is identified. Because of its potential to permanently impair vision or progress to perforation and an open globe, a corneal ulcer is considered an ophthalmologic emergency.

Although most community-acquired cases of bacterial keratitis resolve with empiric therapy and are managed without cultures, cultures are indicated in cases that involve a corneal infiltrate that is central, large, and extends to the middle to deep stroma, cases that are unresponsive to antibiotic therapy, and cases that have atypical clinical features suggestive of fungal, amoebic, or mycobacterial keratitis.[8]

Antibiotic therapy

Low risk of vision loss

Small (< 1 mm), peripheral, nonstaining infiltrate. No epithelial defect. Shallow, minimal anterior chamber reaction, no discharge

Fluoroquinolone eyedrops every 1-2 hours[9]

In contact lens wearers, add tobramycin ointment or ciprofloxacin ointment every bedtime

Medium risk of vision loss

Medium (1-1.5 mm) peripheral infiltrate or any epithelial defect, discharge, or anterior chamber reaction regardless of ulcer size (including small [< 1 mm])

Fluoroquinolone eyedrops every 5 minutes in the ED for 5 doses, then every 1 hour.[9]

Vision threatening

Large (>1.5 mm) and/or central infiltrate, deep anterior chamber inflammation, and/or any scleral involvement

Consult with ophthalmologist immediately, and consider emergent ophthalmology consult in the ED; transfer may be appropriate in order to effect this evaluation.

Two fortified eyedrops every 5 minutes in the ED for 5 doses, tobramycin 15 mg/mL every 1 hour, alternating every 30 minutes with fortified vancomycin 25-50 mg/mL every 1 hour (alternative, cefazolin 50 mg/mL every 1 hour in place of vancomycin)[9]

Consider adding oral or intravenous ciprofloxacin

Cycloplegics

Cycloplegic drops (atropine 1% or cyclopentolate 1% [most common agent]) are applied to provide comfort and to prevent synechiae formation (adhesions between the iris and the lens capsule or cornea, posterior or anterior).

Avoidance of contact lens wear

Contact lens wear should be discontinued until cleared by an ophthalmologist.

Oral pain medications

Pain medication should be given as needed.

Viral infection

If tests results confirm viral infection, begin therapy with mechanical debridement of the infected rim along with a rim of the normal epithelium, followed by topical instillation of antiviral medications.

Fungal infection

A broad-spectrum antifungal drug usually is chosen for fungal infections. Common medications include natamycin, voriconazole, and amphotericin B. Other options include fluconazole, miconazole, and ketoconazole. Natamycin is the first-line treatment in fungal infections of the cornea.[10] Consult with an ophthalmologist.

Consultations

Consulting with an ophthalmologist from the ED is the best practice whenever corneal ulcer is identified. Because of its potential to permanently impair vision or progress to perforation and an open globe, a corneal ulcer is considered an ophthalmologic emergency.

Further Outpatient Care

Most corneal ulcers are managed on an outpatient basis. Consultation with an ophthalmologist from the ED is the best practice whenever a corneal ulcer is identified. 

Further Inpatient Care

Inpatient care is occasionally required, most commonly when the ulcer is vision threatening. Inpatient care may also be required where there are significant issues of compliance with medications or follow-up.

Medication Summary

The goals of pharmacotherapy are to reduce morbidity and prevent complications.

Proparacaine

Clinical Context:  Has a rapid onset of anesthesia that begins within 13-30 sec after instillation. Short duration of action (about 15-20 min). Since prolonged eye anesthesia can eliminate the patient's awareness of mechanical damage to the cornea, do not use outside of the ED. Frequent use of anesthetics may retard healing.

Class Summary

Anesthetics are indicated for pain relief and for conjunctival and corneal scrapings. Local anesthetics stabilize the neuronal membrane and prevent the initiation and transmission of nerve impulses, thereby producing the local anesthetic action.

Cefazolin

Clinical Context:  First-generation cephalosporin antibiotic for gram-positive bacterial coverage. Commonly used in combination with an aminoglycoside to achieve broad-spectrum coverage.

This 50-133 mg/mL solution must be compounded.

Gentamicin (Gentak)

Clinical Context:  Aminoglycoside antibiotic used for gram-negative bacterial coverage. Commonly used in combination with a first-generation cephalosporin.

Erythromycin (PCE, Ery-Tab, Erythrocin Lactobionate, E.E.S.)

Clinical Context:  Indicated for treatment of infections caused by susceptible strains of microorganisms and for prevention of corneal and conjunctival infections.

Ciprofloxacin ophthalmic (Ciloxan)

Clinical Context:  Bactericidal antibiotic that inhibits bacterial DNA synthesis, and consequently growth, by inhibiting DNA gyrase in susceptible organisms.

Indicated for pseudomonal infections and those due to multidrug-resistant gram-negative organisms.

Class Summary

Therapy must cover all likely pathogens in the context of the clinical setting.

Infliximab (Remicade, Inflectra, Renflexis)

Clinical Context:  Chimeric anti-tumor necrosis factor alpha monoclonal antibody. Neutralizes cytokine TNF-alpha and inhibits its binding to TNF-alpha receptor. Mix in 250-mL normal saline for infusion over 2 h. Must use with low-protein-binding filter (1.2 micron or less). Indicated to reduce signs and symptoms of active ankylosing spondylitis.

Class Summary

These agents are used in the treatment of rheumatoid arthritis associated corneal ulcer.

Cyclopentolate (Cyclogyl)

Clinical Context:  Blocks the action of acetylcholine at parasympathetic sites in the smooth muscle, producing pupillary dilation (mydriasis) and paralysis of accommodation (cycloplegia).

Atropine ophthalmic

Clinical Context:  Blocks the action of acetylcholine at parasympathetic sites in the smooth muscle, producing pupillary dilation (mydriasis) and paralysis of accommodation (cycloplegia).

Class Summary

Instillation of a long-acting cycloplegic agent can relax any ciliary muscle spasm that can cause a deep aching pain and photophobia.

Natamycin (Natacyn)

Clinical Context:  Predominantly fungicidal tetraene polyene antibiotic, derived from Streptomyces natalensis that possesses in vitro activity against a variety of yeast and filamentous fungi, including Candida, Aspergillus, Cephalosporium, Fusarium, and Penicillium species. Binds fungal cell membrane forming a polyene sterol complex that alters membrane permeability and depleting essential cellular constituents. Activity against fungi is dose related, but it is not effective in vitro against gram-negative or gram-positive bacteria. Generally, therapy should be continued for 14-21 d or until the fungal keratitis has resolved. In many cases, reducing the dosage gradually at 4-7 d intervals may help ensure that the organism has been eliminated.

Class Summary

Broad-spectrum antifungal agents that cause minimal pain and corneal irritation are recommended. Natamycin is the first-line treatment in fungal infections of the cornea. Candidal infections refractory to natamycin may respond to voriconazole, amphotericin B, miconazole, fluconazole, and ketoconazole. Topical application of these drugs, however, is somewhat limited because most of them must be compounded.

Ibuprofen (Addaprin, Caldolor, Genpril, Dyspel, Motrin, Advil)

Clinical Context:  Usually the DOC for treatment of mild to moderate pain, if no contraindications exist.

Inhibits inflammatory reactions and pain, probably by decreasing the activity of the enzyme cyclooxygenase, which results in prostaglandin synthesis.

Naproxen (Aleve, Naprosyn, Naprelan, Flanax Pain Relief, Anaprox DS)

Clinical Context:  Used for relief of mild to moderate pain. It inhibits inflammatory reactions and pain by decreasing activity of the enzyme cyclooxygenase, resulting in prostaglandin synthesis.

Ketoprofen

Clinical Context:  Used for the relief of mild-to-moderate pain and inflammation. Small doses are initially indicated in small and elderly patients and in those with renal or liver disease. Doses >75 mg do not increase therapeutic effects. Administer high doses with caution, and closely observe patient for response.

Diclofenac (Cambia, Dyloject, Zipsor, Zorvolex)

Clinical Context:  Inhibits prostaglandin synthesis by decreasing activity of enzyme cyclo-oxygenase, which in turn decreases formation of prostaglandin precursors. Has anti-inflammatory, antipyretic, and analgesic properties.

Class Summary

Mechanism of action is believed to be through inhibition of the cyclooxygenase enzyme that is essential in the biosynthesis of prostaglandins. Inhibition of prostaglandin synthesis results in vasoconstriction and decreases in vascular permeability, leukocytosis, and intraocular pressure (IOP). These agents, however, have no significant effect on IOP.

Oxycodone and acetaminophen (Percocet, Endocet, Primlev, Xartemis XR)

Clinical Context:  Drug combination indicated for the relief of moderate to severe pain. Oxycodone inhibits ascending pain pathways by binding to the opiate receptor. Alters the response and perception of pain and produces generalized CNS depression. Acetaminophen inhibits prostaglandin synthesis in the CNS and blocks pain impulse generation peripherally.

Oxycodone and aspirin (Percodan)

Clinical Context:  This drug combination is indicated for the relief of moderate to severe pain. Oxycodone binds to opiate receptors in the central nervous system (CNS), inhibiting the ascending pain pathways, altering pain response and perception. Aspirin inhibits platelet aggregation; has analgesic and ant-inflammatory properties.

Morphine (Arymo ER, Duramorph, Kadian, MS Contin)

Clinical Context:  An opioid analgesic, morphine interacts with endorphin receptors in the CNS, inhibiting the pain pathways, altering pain response and perception.

Codeine and acetaminophen (Tylenol with Codeine #3, Tylenol with Codeine #4)

Clinical Context:  Acetaminophen and codeine combination is used for the treatment of mild to moderate pain.

Hydrocodone and acetaminophen (Hycet, Lorcet, Norco, Vicodin, Zamicet)

Clinical Context:  This combination is used for the relief of moderate to severe pain. Analgesics alter the perception of and response to pain.

Class Summary

Pain control is essential to quality patient care, ensuring patient comfort, promoting pulmonary toilet, and containing sedating properties that benefit patients who experience mild or severe pain.

Trifluridine ophthalmic (Viroptic)

Clinical Context:  A structural analogue of thymidine, this agent inhibits viral DNA polymerase. Viroptic has better penetration through the cornea and greater efficacy (95% heal rate) than other topical agents.

Ganciclovir ophthalmic (Zirgan)

Clinical Context:  Acyclic nucleoside analogue of 2'deoxyguanasine. Phosphorylates first to monophosphate form by viral-encoded protein kinase homologue, then to diphosphate and triphosphate forms by cellular kinases, allowing for greater concentration of ganciclovir in virus-infected cells, possibly due to preferential phosphorylation of ganciclovir in virus-infected cells. Thought to inhibit HSV replication by competitive inhibition of viral DNA polymerases and by incorporating itself into viral DNA, causing termination of viral DNA elongation. Like acyclovir, ganciclovir is virostatic and exerts its effect only on replicating virus.

Class Summary

Therapy of viral infections begins with mechanical debridement of the involved rim along with a rim of normal epithelium. This is followed by the topical instillation of antiviral medications.

What is a corneal ulcer?What is the pathophysiology of corneal ulcers?What is the prevalence of corneal ulcer and ulcerative keratitis?What is the global prevalence of corneal ulcer and ulcerative keratitis?What is the morbidity associated with corneal ulcer and ulcerative keratitis?What are the sexual predilections of corneal ulcer and ulcerative keratitis?Which age groups have the highest prevalence of corneal ulcer and ulcerative keratitis?What is the prevalence of corneal ulcer and ulcerative keratitis in contact lens wearers?What is the prognosis of corneal ulcer and ulcerative keratitis?What is the focus of clinical history in the evaluation of corneal ulcer and ulcerative keratitis?What are the signs and symptoms of corneal ulcer and ulcerative keratitis?What information about contact lens use should be included in the clinical history for corneal ulcer and ulcerative keratitis?What is included in past medical history for corneal ulcer and ulcerative keratitis?Which factors increase the risk for corneal ulcer and ulcerative keratitis?Which physical findings are characteristic of corneal ulcer and ulcerative keratitis?What is the role of visual acuity in the assessment of corneal ulcer and ulcerative keratitis?What is included in the gross exam of corneal ulcer and ulcerative keratitis?What is the role of slit-lamp exam in the assessment of corneal ulcer and ulcerative keratitis?What is the role of fluorescein staining of the cornea in the assessment of corneal ulcer and ulcerative keratitis?What causes corneal ulcer and ulcerative keratitis?What causes bacterial corneal ulcers?What causes viral corneal ulcers?What causes fungal and parasitic corneal ulcers?What are the possible complications of corneal ulcer and ulcerative keratitis?What is the role of lab tests in the workup of corneal ulcer and ulcerative keratitis?Which factors affect the treatment of corneal ulcer and ulcerative keratitis?How are corneal ulcers and ulcerative keratitis with low risk of vision loss treated?How are vision threatening corneal ulcers and ulcerative keratitis treated?How are corneal ulcers and ulcerative keratitis treated in the emergency department (ED)?How are corneal ulcers and ulcerative keratitis with medium risk of vision loss treated?How long should contact lens wear be discontinued in patients with corneal ulcer and ulcerative keratitis?How is pain managed in corneal ulcers and ulcerative keratitis?How are viral corneal ulcers and ulcerative keratitis treated?How are fungal corneal ulcers and ulcerative keratitis treated?Which specialist consultations are beneficial to patients with corneal ulcers and ulcerative keratitis?What further outpatient care is indicated in the treatment of corneal ulcer and ulcerative keratitis?When is inpatient care indicated for the treatment of corneal ulcers and ulcerative keratitis?What is the goal of medical treatment corneal ulcers and ulcerative keratitis?Which medications in the drug class Antivirals, Ophthalmic are used in the treatment of Corneal Ulcer and Ulcerative Keratitis in Emergency Medicine?Which medications in the drug class Analgesics are used in the treatment of Corneal Ulcer and Ulcerative Keratitis in Emergency Medicine?Which medications in the drug class Nonsteroidal anti-inflammatory agents (NSAIDs) are used in the treatment of Corneal Ulcer and Ulcerative Keratitis in Emergency Medicine?Which medications in the drug class Antifungals are used in the treatment of Corneal Ulcer and Ulcerative Keratitis in Emergency Medicine?Which medications in the drug class Cycloplegics are used in the treatment of Corneal Ulcer and Ulcerative Keratitis in Emergency Medicine?Which medications in the drug class Antirheumatic, disease-modifying agents are used in the treatment of Corneal Ulcer and Ulcerative Keratitis in Emergency Medicine?Which medications in the drug class Antibiotics are used in the treatment of Corneal Ulcer and Ulcerative Keratitis in Emergency Medicine?Which medications in the drug class Anesthetics are used in the treatment of Corneal Ulcer and Ulcerative Keratitis in Emergency Medicine?

Author

Jesse Borke, MD, FACEP, FAAEM, Associate Medical Director, Department of Emergency Medicine, Los Alamitos Medical Center

Disclosure: Nothing to disclose.

Coauthor(s)

Audrey Xi Tai, DO, MS, Assistant Clinical Professor of Ophthalmology, Gavin Herbert Eye Institute, University of California, Irvine, School of Medicine

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Barry E Brenner, MD, PhD, FACEP, Professor of Emergency Medicine, Professor of Internal Medicine, Program Director for Emergency Medicine, Sanz Laniado Medical Center, Netanya, Israel

Disclosure: Nothing to disclose.

Additional Contributors

Lisa Diane Mills, MD, Associate Professor of Emergency Medicine, University of California, Davis, School of Medicine

Disclosure: Nothing to disclose.

Trevor John Mills, MD, MPH, Chief of Emergency Medicine, Veterans Affairs Northern California Health Care System; Professor of Emergency Medicine, Department of Emergency Medicine, University of California, Davis, School of Medicine

Disclosure: Nothing to disclose.

William K Chiang, MD, Associate Professor, Department of Emergency Medicine, New York University School of Medicine; Chief of Service, Department of Emergency Medicine, Bellevue Hospital Center

Disclosure: Nothing to disclose.

Acknowledgements

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous authors, Jerome FX Naradzay, MD, and Wesley S Grigsby, MD, to the development and writing of this article.

References

  1. Jeng BH, Gritz DC, Kumar AB, et al. Epidemiology of ulcerative keratitis in Northern California. Arch Ophthalmol. 2010 Aug. 128(8):1022-8. [View Abstract]
  2. Kosker M, Duman F, Suri K, Hammersmith KM, Nagra PK, Rapuano CJ. Long-term Results of Keratoplasty in Patients With Herpes Zoster Ophthalmicus. Cornea. 2013 Mar 27. [View Abstract]
  3. French DD, Margo CE. Demographic patterns of ED patients diagnosed as having corneal ulcer. Am J Emerg Med. 2013 May 17. [View Abstract]
  4. Morgan PB, Efron N, Brennan NA, et al. Risk factors for the development of corneal infiltrative events associated with contact lens wear. Invest Ophthalmol Vis Sci. 2005 Sep. 46(9):3136-43. [View Abstract]
  5. Efron N, Morgan PB, Hill EA, et al. Incidence and morbidity of hospital-presenting corneal infiltrative events associated with contact lens wear. Clin Exp Optom. 2005 Jul. 88(4):232-9. [View Abstract]
  6. Rasoulinejad SA, Sadeghi M, Montazeri M, Hedayati Goudarzi H, Montazeri M, Akbarian N. Clinical Presentation and Microbial Analyses of Contact Lens Keratitis; an Epidemiologic Study. Emerg (Tehran). 2014 Fall. 2 (4):174-7. [View Abstract]
  7. Kehe K, Szinicz L. Medical aspects of sulphur mustard poisoning. Toxicology. 2005 Oct 30. 214(3):198-209. [View Abstract]
  8. [Guideline] AAO Cornea/External Disease Preferred Practice Patterns Panel, Bacterial Keratitis PPP – OCT 2013. American Academy of Ophthalmology. Available at https://www.aao.org/preferred-practice-pattern/bacterial-keratitis-ppp--2013. October 2013;
  9. The Wills Eye Manual: Office and Emergency Room Diagnosis and Treatment of Eye Disease. Philadelphia: Lippincott; 1994.
  10. Loh AR, Hong K, Lee S, Mannis M, Acharya NR. Practice patterns in the management of fungal corneal ulcers. Cornea. 2009 Sep. 28(8):856-9. [View Abstract]
  11. [Guideline] American Academy of Ophthalmology Cornea/External Disease Panel, Preferred Practice Patterns Committee. Bacterial keratitis. San Francisco (CA): American Academy of Ophthalmology (AAO); 2008.
  12. Park J, Lee KM, Zhou H, Rabin M, Jwo K, Burton WB, et al. Community practice patterns for bacterial corneal ulcer evaluation and treatment. Eye Contact Lens. 2015 Jan. 41 (1):12-8. [View Abstract]
  13. Sharma N, Arora T, Jain V, Agarwal T, Jain R, Jain V, et al. Gatifloxacin 0.3% Versus Fortified Tobramycin-Cefazolin in Treating Nonperforated Bacterial Corneal Ulcers. Cornea. 2015 Oct 27. [View Abstract]
  14. Miller D. Pharmacological treatment for infectious corneal ulcers. Expert Opin Pharmacother. 2013 Apr. 14(5):543-60. [View Abstract]
  15. Acharya NR, Srinivasan M, Mascarenhas J, et al. The steroid controversy in bacterial keratitis. Arch Ophthalmol. 2009 Sep. 127(9):1231. [View Abstract]
  16. Araki-Sasaki K, Nishi I, Yonemura N, et al. Characteristics of Pseudomonas corneal infection related to orthokeratology. Cornea. 2005 Oct. 24(7):861-3. [View Abstract]
  17. Clewes AR, Dawson JK, Kaye S, Bucknall RC. Peripheral ulcerative keratitis in rheumatoid arthritis: successful use of intravenous cyclophosphamide and comparison of clinical and serological characteristics. Ann Rheum Dis. 2005 Jun. 64(6):961-2. [View Abstract]
  18. Frith P, Gray R, MacLennan S. The Eye in Clinical Practice. 1994. 77-95.
  19. Goldberg DF, Negvesky GJ, Butrus SI, et al. Ulcerative keratitis in mycosis fungoides. Eye Contact Lens. 2005 Sep. 31(5):219-20. [View Abstract]
  20. Höfling-Lima AL, de Freitas D, Sampaio JL, et al. In vitro activity of fluoroquinolones against Mycobacterium abscessus and Mycobacterium chelonae causing infectious keratitis after LASIK in Brazil. Cornea. 2005 Aug. 24(6):730-4. [View Abstract]
  21. Int Ophthalmol Clin. Contact lenses and external disease. Int Ophthalmol Clin. 1986. 26(1):1-166. [View Abstract]
  22. Khanal B, Deb M, Panda A, et al. Laboratory diagnosis in ulcerative keratitis. Ophthalmic Res. 2005 May-Jun. 37(3):123-7. [View Abstract]
  23. Krachmer JH, Mannis MJ, Holland EJ. Cornea: Fundamentals of Cornea and External Disease. 1997. 403-407.
  24. Leibowitz HM. Corneal Disorders: Clinical Diagnosis and Management. 1984. 353-372.
  25. Mirza SH. Fungal keratitis due to fusarium solani. J Coll Physicians Surg Pak. 2005 Sep. 15(9):576-7. [View Abstract]
  26. O'Donnell C, Efron N. Contact lens wear and diabetes mellitus. Cont Lens Anterior Eye. 1998. 21(1):19-26. [View Abstract]
  27. Pichare A, Patwardhan N, Damle AS, et al. Bacteriological and mycological study of corneal ulcers in and around Aurangabad. Indian J Pathol Microbiol. 2004 Apr. 47(2):284-6. [View Abstract]
  28. Pinna A, Sechi LA, Zanetti S, et al. Detection of virulence factors in a corneal isolate of Klebsiella pneumoniae. Ophthalmology. 2005 May. 112(5):883-7. [View Abstract]
  29. Seino JY, Anderson SF. Mooren's ulcer. Optom Vis Sci. 1998 Nov. 75(11):783-90. [View Abstract]
  30. Servat JJ, Ramos-Esteban JC, Tauber S, et al. Mycobacterium chelonae-Mycobacterium abscessus complex clear corneal wound infection with recurrent hypopyon and perforation after phacoemulsification and intraocular lens implantation. J Cataract Refract Surg. 2005 Jul. 31(7):1448-51. [View Abstract]
  31. Thomas JW, Pflugfelder SC. Therapy of progressive rheumatoid arthritis-associated corneal ulceration with infliximab. Cornea. 2005 Aug. 24(6):742-4. [View Abstract]
  32. Vaughan D, Asbury T, Riordan-Eva P. General Ophthalmology. 1995. 124-133.
  33. Velasco Cruz AA, Attie-Castro FA, Fernandes SL, et al. Adult blindness secondary to vitamin A deficiency associated with an eating disorder. Nutrition. 2005 May. 21(5):630-3. [View Abstract]
  34. Verhelst D, Koppen C, Van Looveren J, et al. Clinical, epidemiological and cost aspects of contact lens related infectious keratitis in Belgium: results of a seven-year retrospective study. Bull Soc Belge Ophtalmol. 2005. 7-15. [View Abstract]
  35. Zaher SS, Sandinha T, Roberts F, et al. Herpes simplex keratitis misdiagnosed as rheumatoid arthritis-related peripheral ulcerative keratitis. Cornea. 2005 Nov. 24(8):1015-7. [View Abstract]

Peripheral ulcerative keratitis in the right eye of a patient with rheumatoid arthritis. Glue has been placed.

Peripheral ulcerative keratitis in the right eye of a patient with rheumatoid arthritis. Glue has been placed.